American Society of Clinical Oncology

SHERPA: White

People

  1. Horwitz
    Horwitz
  2. Zelenetz
    Zelenetz
  3. Hamlin
    Hamlin
  4. Moskowitz
    Moskowitz
  5. Noy
    Noy
  6. Palomba
    Palomba
  7. Schoder
    Schoder
  8. Kumar
    Kumar
  9. Yahalom
    Yahalom
  10. Drullinsky
    Drullinsky

Groups

  1. Center for Hematologic Malignancies (17)
  2. Department of Medicine (17)
  3. Hematologic Malignancies, Division of (17)
  4. Lymphoma (17)
  5. Population Sciences Research Program (17)
  6. Survivorship Research (11)
  7. Radiology, Department of (9)
  8. Epidemiology and Biostatistics (7)
  9. Advanced Practice Providers (6)
  10. Molecular Imaging and Therapy Service (6)
Search Within
  1. "Andrew Zelenetz"
  2. "Steven Horwitz"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (6)
Groups
  1. Center for Hematologic Malignancies (17)
  2. Department of Medicine (17)
  3. Hematologic Malignancies, Division of (17)
  4. Lymphoma (17)
  5. Population Sciences Research Program (17)
  6. Survivorship Research (11)

More Groups

People
  1. Andrew Zelenetz (17)
  2. Steven Horwitz (17)
  3. Craig Moskowitz (12)
  4. David Straus (12)
  5. Paul Hamlin (11)
  6. Matthew Matasar (10)

More People

Years
  1. 2021 (3)
  2. 2020 (3)
  3. 2017 (1)
  4. 2015 (2)
  5. 2014 (1)
  6. 2013 (1)

More Years

Publications
  1. Journal of Clinical Oncology (17)

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial
    Meeting Abstract

    Owens, C. N.; Iannotta, A.; Gerecitano, J. F.; Matasar, M. J.; Noy, A.; Moskowitz, C. H.; Drullinsky, P.; Palomba, M. L.; Straus, D. J.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma
    Meeting Abstract

    Mehta-Shah, N; Lunning, M. A.; Boruchov, A. M.; Ruan, J.; Nair, S.; Lynch, P.; Byrne, R.; Moskowitz, A. J.; Matasar, M. J.; Gerecitano, J. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save